NasdaqCM - Nasdaq Real Time Price USD

Radiopharm Theranostics Limited (RADX)

0.8900 -0.1031 (-10.38%)

As of 1:59:54 PM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Radiopharm Theranostics Reports Business Update

GlobeNewswire 1d ago

RADX
-10.38%
Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101

GlobeNewswire 29d ago

RADX
-10.38%
Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma

GlobeNewswire 1mo ago

RADX
-10.38%
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors

GlobeNewswire 2mo ago

RADX
-10.38%
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial

GlobeNewswire 2mo ago

RADX
-10.38%
Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

GlobeNewswire 2mo ago

RADX
-10.38%
RADX: RAD101 Topline & FY:26 Cash Flows

Zacks Small Cap Research 2mo ago

RADX
-10.38%
GE HealthCare Wins Approval for MINItrace Magni Cyclotron in Europe

Zacks 14d ago

GEHC

LNTH

TLX
Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting

GlobeNewswire 1mo ago

RADX
-10.38%
Radiopharm Theranostics Reports Business Update

GlobeNewswire 3mo ago

RADX
-10.38%
Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan

GlobeNewswire 3mo ago

RADX
-10.38%
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

GlobeNewswire 3mo ago

RADX
-10.38%

Performance Overview

Return	RADX	S&P/ASX 200 [XJO] (^AXJO)
YTD	-82.95%	+1.98%
1-Year	-81.76%	+0.83%
3-Year	-84.11%	+27.35%

U.S. markets close in 1h 6m

Radiopharm Theranostics Limited (RADX)

Radiopharm Theranostics Reports Business Update

Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101

Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

RADX: RAD101 Topline & FY:26 Cash Flows

GE HealthCare Wins Approval for MINItrace Magni Cyclotron in Europe

Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting

Radiopharm Theranostics Reports Business Update

Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy